Navigation Links
HemoShear Announces Advancement of Predictive Drug Safety Systems

CHARLOTTESVILLE, Va., July 18, 2013 /PRNewswire/ -- HemoShear, LLC, a leading developer of human-relevant systems for drug development and discovery, today announced an important milestone in the development of systems that predict safety of new drugs and chemicals. Published in the American Journal of Physiology – Cell Physiology, the manuscript entitled "Hemodynamic flow improves rat hepatocyte morphology, function and metabolic activity in vitro" reports HemoShear's success in applying the core principles of its technology to replicate liver biology on the laboratory bench.  Development of non-human species systems is an important step towards systems that use human cells to predict drug and chemical effects in humans. 

(Logo: )

HemoShear's work is valuable to the pharmaceutical industry because drug-induced liver injury, which is often not detected in pre-clinical animal and cell-culture studies, remains the most frequent cause of drug-induced toxicity and toxicity-related failures in clinical trials.  By accurately replicating organ and disease biology in the laboratory, HemoShear's human-relevant systems will reduce the risk of costly failures in clinical trials and accelerate development of safe and effective drugs in humans. 

Ajit Dash, M.D., Ph.D., HemoShear's Senior Director of Liver Systems, explains the significance of HemoShear's achievement.  "In contrast to traditional methods that do not provide critical physiological cues to restore human cell biology, HemoShear's principles of combining primary cells and fluid circulation patterns restore the most important biological functions of hepatocytes, which are necessary for prediction of drug metabolism and safety," said Dr. Dash.

"Our work on the rat system has enabled significant progress in developing a human liver surrogate system, which is currently being validated with known drugs.  HemoShear has already validated a physiologically accurate vascular system and vascular disease conditions.  By gaining access to our liver and vascular systems and diseases, our pharmaceutical partners can save millions of dollars by avoiding drugs that are doomed to fail, while redirecting precious resources to drug candidates that are more likely to succeed in humans," said Brian Wamhoff, Ph.D., HemoShear's co-founder and Vice President of R&D.

HemoShear's publication may be found at the following address:

Dash A, Simmers MB, Deering TG, Berry DJ, Feaver RE, Hastings NE, Pruett TL, Lecluyse EL, Blackman BR, Wamhoff BR. Hemodynamic Flow Improves Rat Hepatocyte Morphology, Function and Metabolic Activity in vitro. Am J Physiol Cell Physiol. 2013 Mar 13 [Epub ahead of print]

About HemoShear, LLC

By applying physiologically accurate hemodynamics and biological transport to primary cell cultures, HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases for applications throughout drug discovery and development. Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies. HemoShear's science leads to new medicines and improves human health.  

For information about HemoShear, please visit

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems
2. HemoShear Relocates and Expands Operations to Historic Martha Jefferson Property in Charlottesville, Virginia
3. HemoShear Adds Industry Veterans Mehmood Khan and Fred Brown to Board of Managers
4. HemoShear Unveils In Vitro Steatosis System at Annual Meeting of the Association for the Study of Liver Diseases
5. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
6. Cardium Announces Reverse Stock Split
7. STAAR Surgical Announces Second Quarter 2013 Results Release Date And Conference Call And Webcast
8. RXi Pharmaceuticals Announces CEO Interview
9. Bureau Veritas Announces Sargam Laboratory Private Limited Name Change
10. Comco Plastics Inc. Announces Its Expansion & Separation From The NYTEF Group.
11. Hill-Rom Announces Preliminary Fiscal 2013 Third Quarter Results and Search for New CFO; Adjusted Earnings Per Share Expected to be in Line with Guidance
Post Your Comments:
(Date:12/1/2015)... 2015 ... of the "2016 Europe Enteric ... Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, ... offering. --> ) ... "2016 Europe Enteric Disease Testing ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... Dec. 1, 2015   Craneware, Inc ., ... solutions, today announced the company will showcase a ... ® solution at the American Society ... Meeting . The new features are focused on ... monitoring and managing enterprise-wide pharmacy charges to ensure ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center Jacksonville ... is the only hospital in the region providing what is known as the ... pacing patients were revealed recently at a medical conference and published in The ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 ... of the company’s growing product line of food safety and seafood fraud prevention ... (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for the ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic foot wounds ... Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a health care ... to diseases of the diabetic foot. The American Board of Multiple Specialties ...
(Date:12/1/2015)... ... 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, 2015) ... has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) service ... special needs providers that excel in synthesizing the areas of clinical quality, staff ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest white paper, “ ... a main “pain point” for merging or aligning healthcare provider organizations—when mergers and ... signed. This quick-read guidance suggests that failing to recognize the power of ...
Breaking Medicine News(10 mins):